Takashi Kijima

5.3k total citations
167 papers, 3.4k citations indexed

About

Takashi Kijima is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Takashi Kijima has authored 167 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 111 papers in Pulmonary and Respiratory Medicine, 78 papers in Oncology and 21 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Takashi Kijima's work include Lung Cancer Treatments and Mutations (46 papers), Occupational and environmental lung diseases (43 papers) and Lung Cancer Research Studies (34 papers). Takashi Kijima is often cited by papers focused on Lung Cancer Treatments and Mutations (46 papers), Occupational and environmental lung diseases (43 papers) and Lung Cancer Research Studies (34 papers). Takashi Kijima collaborates with scholars based in Japan, United States and China. Takashi Kijima's co-authors include Ravi Salgia, Gautam Maulik, C. Patrick, Bruce E. Johnson, Martin Sattler, Isao Tachibana, Yoshito Takeda, Ichiro Kawase, Toru Kumagai and Paul T. Morrison and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Takashi Kijima

153 papers receiving 3.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Takashi Kijima Japan	26	1.4k	1.3k	1.2k	508	392	167	3.4k
Hisanori Uehara Japan	39	1.7k 1.3×	2.3k 1.8×	1.7k 1.4×	233 0.5×	719 1.8×	135	5.1k
Gerald W. Prager Austria	32	1.7k 1.2×	1.0k 0.8×	802 0.7×	164 0.3×	316 0.8×	171	3.5k
Tetsuji Sawada Japan	41	1.5k 1.1×	1.8k 1.4×	1.1k 0.9×	168 0.3×	884 2.3×	166	5.1k
Naoya Ikeda Japan	27	1.6k 1.2×	768 0.6×	473 0.4×	456 0.9×	546 1.4×	93	2.9k
T.R. Jeffry Evans United Kingdom	36	1.9k 1.4×	1.8k 1.4×	686 0.6×	510 1.0×	333 0.8×	107	4.4k
Darren R. Carpizo United States	27	1.4k 1.0×	1.5k 1.1×	325 0.3×	367 0.7×	151 0.4×	80	3.0k
Peter Vermeulen Belgium	35	2.3k 1.7×	1.4k 1.1×	776 0.6×	436 0.9×	360 0.9×	79	4.0k
David R. Shalinsky United States	27	1.7k 1.2×	2.3k 1.7×	1.0k 0.8×	167 0.3×	272 0.7×	52	4.3k
Shinichi Sakamoto Japan	30	545 0.4×	1.4k 1.1×	799 0.7×	323 0.6×	223 0.6×	197	3.3k
Yasushi Ichikawa Japan	43	2.4k 1.8×	1.4k 1.0×	1.0k 0.8×	461 0.9×	281 0.7×	247	5.0k

Countries citing papers authored by Takashi Kijima

Since Specialization

Citations

This map shows the geographic impact of Takashi Kijima's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Takashi Kijima with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Takashi Kijima more than expected).

Fields of papers citing papers by Takashi Kijima

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Takashi Kijima. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Takashi Kijima. The network helps show where Takashi Kijima may publish in the future.

Co-authorship network of co-authors of Takashi Kijima

This figure shows the co-authorship network connecting the top 25 collaborators of Takashi Kijima. A scholar is included among the top collaborators of Takashi Kijima based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Takashi Kijima. Takashi Kijima is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fujimoto, Daichi, Ryota Shibaki, Keiichi Kimura, et al.. (2025). Identification of key gene signatures for predicting chemo-immunotherapy efficacy in extensive-stage small-cell lung cancer using machine learning. Lung Cancer. 199. 108079–108079. 1 indexed citations

Hata, Akito, Yoshihito Kogure, Masahide Oki, et al.. (2024). Radiation therapy (RT)-free pembrolizumab plus chemotherapy (P+C) for PD-L1 TPS ≥50% locally advanced non-small cell lung cancer (LA-NSCLC): Primary analysis from multicenter single arm phase II study (Evolution trial; WJOG11819L).. Journal of Clinical Oncology. 42(17_suppl). LBA8050–LBA8050.

Hayashi, Hidetoshi, Makoto Nishio, Hiroaki Akamatsu, et al.. (2024). Association between Immune-Related Adverse Events and Atezolizumab in Previously Treated Patients with Unresectable Advanced or Recurrent Non–Small Cell Lung Cancer. Cancer Research Communications. 4(11). 2858–2867. 2 indexed citations

Kuribayashi, Kozo, Naoki Kawamura, Takeshi Kondo, et al.. (2024). P4.14C.02 Analysis of Pleiotropic Effects of Nivolumab in Patients with Relapsed Pleural Mesothelioma: A Single Center Retrospective Study. Journal of Thoracic Oncology. 19(10). S408–S409.

Miyauchi, Eisaku, Kadoaki Ohashi, Atsushi Osoegawa, et al.. (2024). J-TAIL-2: A Prospective, Observational Study of Atezolizumab Combined With Carboplatin and Etoposide in Patients With Extensive-Stage SCLC in Japan. JTO Clinical and Research Reports. 6(3). 100783–100783.

Hashimoto, Masaki, Seiji Matsumoto, Nobuyuki Kondo, et al.. (2024). Impact of Operation on Disease Progression and Survival of Patients With Pleural Mesothelioma. The Annals of Thoracic Surgery. 118(1). 216–223. 5 indexed citations

Iwasaku, Masahiro, Junji Uchino, Takahiro Yamada, et al.. (2023). Prophylactic treatment of dacomitinib‐induced skin toxicities in epidermal growth factor receptor‐mutated non–small‐cell lung cancer: A multicenter, Phase II trial. Cancer Medicine. 12(14). 15117–15127. 3 indexed citations

Morimoto, Kenji, Tadaaki Yamada, Tadaaki Yamada, et al.. (2021). Clinical impact of pembrolizumab combined with chemotherapy in elderly patients with advanced non-small-cell lung cancer. Lung Cancer. 161. 26–33. 39 indexed citations

Morise, Masahiro, Hiroshi Sakai, Terufumi Kato, et al.. (2021). MO19-2 INSIGHT2: Tepotinib + osimertinib in pts with EGFR-mutant NSCLC and acquired resistance to 1L osimertinib due to METamp. Annals of Oncology. 32. S309–S309.

10.

Nakajima, Y., Kozo Kuribayashi, Akio Tada, et al.. (2020). Adenosine Deaminase in Pleural Effusion and Its Relationship with Clinical Parameters in Patients with Malignant Pleural Mesothelioma. Cancer Investigation. 38(6). 356–364. 7 indexed citations

11.

Hayashi, Hidetoshi, M. Okada, Takashi Kijima, et al.. (2020). 1895MO Three-year follow-up results of the MERIT trial: A Japanese phase II study of nivolumab in malignant pleural mesothelioma. Annals of Oncology. 31. S1076–S1076. 2 indexed citations

12.

Koba, Taro, Seigo Minami, Kentaro Masuhiro, et al.. (2018). Phase II trial of induction chemotherapy of pemetrexed plus split-dose cisplatin followed by pemetrexed maintenance for untreated non-squamous non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology. 82(1). 111–117. 2 indexed citations

13.

Minami, Toshiyuki, Yuhei Kinehara, Shingo Kanemura, et al.. (2018). Challenges for the development of immunotherapy in small-cell lung cancer. Medical Research Archives. 6(6). 1 indexed citations

14.

Takahashi, Ryo, Haruhiko Hirata, Isao Tachibana, et al.. (2011). Early [18F]Fluorodeoxyglucose Positron Emission Tomography at Two Days of Gefitinib Treatment Predicts Clinical Outcome in Patients with Adenocarcinoma of the Lung. Clinical Cancer Research. 18(1). 220–228. 78 indexed citations

15.

Nakanishi, Kaori, Yoshito Takeda, Satoshi Tetsumoto, et al.. (2011). Involvement of Endothelial Apoptosis Underlying Chronic Obstructive Pulmonary Disease–like Phenotype in Adiponectin-null Mice: Implications for Therapy. American Journal of Respiratory and Critical Care Medicine. 183(9). 1164–1175. 57 indexed citations

16.

Tetsumoto, Satoshi, Akio Osa, Takashi Kijima, et al.. (2011). Two cases of leptomeningeal metastases from lung adenocarcinoma which progressed during gefitinib therapy but responded to erlotinib. International Journal of Clinical Oncology. 17(2). 155–159. 14 indexed citations

17.

Suzuki, Mayumi, Isao Tachibana, Yoshito Takeda, et al.. (2009). Tetraspanin CD9 Negatively Regulates Lipopolysaccharide-Induced Macrophage Activation and Lung Inflammation. The Journal of Immunology. 182(10). 6485–6493. 70 indexed citations

18.

Nagatomo, Izumi, Toru Kumagai, Tadahiro Yamadori, et al.. (2007). Gefitinib-Sensitive EGFR Lacking Residues 746–750 Exhibits Hypophosphorylation at Tyrosine Residue 1045, Hypoubiquitination, And Impaired Endocytosis. DNA and Cell Biology. 26(3). 178–185. 14 indexed citations

19.

Yoneda, Tsutomu, Toru Kumagai, Izumi Nagatomo, et al.. (2006). The Extracellular Domain of p185 ^c-neu Induces Density-Dependent Inhibition of Cell Growth in Malignant Mesothelioma Cells and Reduces Growth of Mesothelioma In Vivo. DNA and Cell Biology. 25(9). 530–540. 1 indexed citations

20.

Nagatomo, Izumi, Toru Kumagai, Tadahiro Yamadori, et al.. (2006). The Gefitinib-Sensitizing Mutant Epidermal Growth Factor Receptor Enables Transformation of a Mouse Fibroblast Cell Line. DNA and Cell Biology. 25(4). 246–251. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact